Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease
- PMID: 19243073
- DOI: 10.1002/mds.22485
Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease
Abstract
Therapeutic trials in Huntington's disease (HD) are challenging as clinical progression is slow and variable and reliable biomarkers are lacking. We used magnetic resonance imaging and the brain boundary shift integral to quantify whole-brain atrophy rates over 1 year in early and premanifest HD subjects, and controls. Early HD subjects had statistically significantly (P = 0.007) increased (threefold higher) rates of whole-brain atrophy compared with controls. Higher atrophy rates were associated with longer CAG repeat length. MRI-based measures of whole-brain atrophy may have potential as a measure of progression in HD.
(c) 2009 Movement Disorder Society.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
